医学
肝细胞癌
肝癌
阶段(地层学)
内科学
胃肠病学
生物
古生物学
作者
David Martín,Héloïse Smet,Ana Cristina Da Silva Costa,Nermin Halkic,Émilie Uldry,Parissa Tabrizian,Myron Schwarz,Ahmad Mahamid,Claire Goumard,Olivier Scatton,Julie Périnel,Mustapha Adham,Nicolas Demartines,Emmanuel Melloul
出处
期刊:Hpb
[Elsevier BV]
日期:2023-07-01
卷期号:25 (7): 836-844
被引量:1
标识
DOI:10.1016/j.hpb.2023.04.001
摘要
Background According to the Barcelona Clinic Liver Cancer (BCLC) staging system, liver resection (LR) is recommended for early-stage (BCLC-A) hepatocellular carcinoma (HCC) but not for intermediate-stage (BCLC-B). This study aimed to assess the outcomes of LR in these patients using a subclassification tumour burden score (TBS). Methods All consecutive patients that underwent LR for BCLC-A and BCLC-B HCC between 01/2010 and 12/2020 in 4 tertiary referral centers were included. Clinical outcomes and overall survival (OS) were assessed in relation to TBS and BCLC stages. Results Among 612 patients included, 562 were classified as BCLC-A and 50 as BCLC-B. The incidence of overall postoperative complications (56.0 vs 41.5%, p = 0.053) and mortality (0 vs 1.6%, p = 1.000) were similar between BCLC-A and BCLC-B patients. OS was significantly higher for BCLC A/low TBS than BCLC B/low TBS (p = 0.009), while patients with medium and high TBS had similar OS, irrespective of BCLC stage (respectively p = 0.103 and p = 0.343). Conclusions Patients with medium and high TBS had comparable OS and DFS, irrespective of BCLC A or B stage, and postoperative morbidity was comparable. These results highlight the need for refinement of the BCLC staging system, and LR could be considered for selected intermediate stage (BCLC-B) according to the tumour burden.
科研通智能强力驱动
Strongly Powered by AbleSci AI